We therefore used A-1155463 instead of its more orally bioavailable counterpart A-1331852 in our in vivo experiments, which showed considerable efficacy in reducing adenoma outgrowth with no observed toxicity, indicating potential for less orally bioavailable BCL-XL inhibitors in CRC therapy. The gene discussed is BCL2L1; the disease is colorectal carcinoma.